NVCR News and Press, NovoCure Limited From 08/09/22

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

After suffering the worst six months for stocks to start a year in more than half a century, investors received a bit of a reprieve in July. Some may be wondering if they missed the boat, and others may still be fearing the worst is yet to come for their portfolio. But the best course of ac...

NovoCure printed another successful quarter with upsides in revenue, but came in behind consensus below the bottom line. In particular, it made further inroads on its TTFields footprint, and this continues to be a key inflection point for the stock. Despite the constructive quarte...

Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q2 2022 Earnings Call Jul 28, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q2 2022 Earnings Call Transcript

Novocure Ltd (NVCR) Q2 2022 Earnings Conference Call July 28, 2022, 08:00 ET Company Participants Ingrid Goldberg - VP, IR William Doyle - Executive Chairman Ashley Cordova - CFO Asaf Danziger - President, CEO & Director Uri Weinberg - Chief Science O...

NovoCure ( NASDAQ: NVCR ) is trading ~ 10% down after it posted wider-than-expected loss as costs increased during the quarter. The company posted Q2 GAAP EPS of -$0.23, which missed estimates by $0.09. NVCR also said top-line data from the LUNAR pivotal st...

NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.23 misses by $0.09 . Revenue of $140.9M (+5.5% Y/Y) beats by $5.77M . Shares -1.9% PM. As of June 30, 2022, there were 3,454 active patients on therapy. Active patients from North America, EMEA...

Quarterly net revenues of $140.9 million, a 6% increase year-over-year Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cance...

NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$0.14 (flat Y/Y) and the consensus Revenue Estimate is $135.13M (+1.2% Y/Y). Over the last 3 months, EPS estimates have see...

Awards aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure today announced the recipients of the 4 th Annual AACR-Novocure Grants for Tumor Treating Fields Res...